Sakakibara, Toshihiro
Shindo, Yuichiro
Kobayashi, Daisuke
Sano, Masahiro
Okumura, Junya
Murakami, Yasushi
Takahashi, Kunihiko
Matsui, Shigeyuki
Yagi, Tetsuya
Saka, Hideo
Hasegawa, Yoshinori
Article History
Received: 19 October 2021
Accepted: 29 December 2021
First Online: 12 January 2022
Declarations
:
: The study protocol adhered to the Declaration of Helsinki and the Japanese Ethics Guidelines for Epidemiological Studies. The study was approved by the ethics committee of Nagoya University and respective institutional review boards of the participating institutions. Informed consent of the participants was waived, but the opt-out method was adopted according to the ethics guidelines.
: Not applicable.
: All of the following information provide relevant financial activities outside the submitted work. Dr. Shindo reports personal fees (payment for lectures including service on speakers bureaus) from Pfizer Inc., Shionogi & Co., Ltd., MSD K.K., Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., KYORIN Pharmaceutical Co.,Ltd., DAIICHI SANKYO COMPANY, LIMITED, and Nippon Boehringer Ingelheim Co., Ltd. Dr. Yagi reports grants and personal fees (payment for lectures including service on speakers bureaus) from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Asahi Kasei Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., Astellas Pharma Inc., Dainippon Sumitomo Pharma Co., Ltd., Mitsubishi Tanabe Pharma., MSD K.K, Beckton Dickinson and Company, Saraya Co., Ltd., KYORIN Pharmaceutical Co.,Ltd., Beckman Coulter, Inc., TERUMO CORPORATION, Oxford Immunotec Ltd., MIYARISAN PHARMACEUTICAL CO., Kao Professional Services, and Kyowa Hakko Kirin Co., Ltd. Dr. Saka reports grants from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Bristol-Myers Squibb Company, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim Co., Ltd., MSD K.K., Eli Lilly Japan K. K., Daiichi Sankyo CO., LTD., Astrazeneca K. K., Novartis Phama K. K., Taiho Pharmaceutical Co., LTD., Sanofi K. K., and Bayer Yakuhin, Ltd. Dr. Hasegawa reports grants and personal fees (payment for lectures including service on speakers bureaus) from Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K.K., and Pfizer Japan Inc.